Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Ian Clements bought 4,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were bought at an average cost of $11.51 per share, for a total transaction of $46,040.00.
Shares of MIRM traded down $0.05 during trading hours on Wednesday, hitting $10.13. 3,576 shares of the stock were exchanged, compared to its average volume of 45,832. Mirum Pharmaceuticals has a fifty-two week low of $9.25 and a fifty-two week high of $15.50. The business’s 50-day simple moving average is $13.15.
Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 28th. The company reported ($2.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($1.83). On average, equities research analysts anticipate that Mirum Pharmaceuticals will post -2.14 EPS for the current fiscal year.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Featured Article: Oversold
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.